Our findings confirm that patients with NAD+ deficiency syndromes can display characteristics previously described for CMS and therefore mutations in enzymes of the tryptophan catabolic pathway should be excluded in patients diagnosed with CMS not carrying mutations in TGDS. Here, TGDS is linked to congenital myasthenic syndrome.